このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Zydus Wellness マネジメント

マネジメント基準チェック /44

Zydus Wellness'の CEO はTarun Aroraで、 Jan2019年に任命され、の在任期間は 5.42年です。の年間総報酬は₹ 12.54Mで、 100%給与と0%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.003%を直接所有しており、その価値は₹ 3.83M 。経営陣と取締役会の平均在任期間はそれぞれ5.4年と6.5年です。

主要情報

Tarun Arora

最高経営責任者

₹12.5m

報酬総額

CEO給与比率	100.0%
CEO在任期間	5.4yrs
CEOの所有権	0.003%
経営陣の平均在職期間	5.4yrs
取締役会の平均在任期間	6.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Zydus Wellness の収益と比較して、Tarun Arora の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	₹3b
Dec 31 2023	n/a	n/a	₹3b
Sep 30 2023	n/a	n/a	₹3b
Jun 30 2023	n/a	n/a	₹3b
Mar 31 2023	₹13m	₹13m	₹3b
Dec 31 2022	n/a	n/a	₹3b
Sep 30 2022	n/a	n/a	₹3b
Jun 30 2022	n/a	n/a	₹3b
Mar 31 2022	₹12m	₹12m	₹3b
Dec 31 2021	n/a	n/a	₹3b
Sep 30 2021	n/a	n/a	₹3b
Jun 30 2021	n/a	n/a	₹2b
Mar 31 2021	₹13m	₹13m	₹1b
Dec 31 2020	n/a	n/a	₹547m
Sep 30 2020	n/a	n/a	₹572m
Jun 30 2020	n/a	n/a	₹2b
Mar 31 2020	₹11m	₹11m	₹1b
Dec 31 2019	n/a	n/a	₹1b
Sep 30 2019	n/a	n/a	₹2b
Jun 30 2019	n/a	n/a	₹2b
Mar 31 2019	₹33m	₹33m	₹2b
Dec 31 2018	n/a	n/a	₹1b
Sep 30 2018	n/a	n/a	₹1b
Jun 30 2018	n/a	n/a	₹1b
Mar 31 2018	₹30m	₹30m	₹1b

報酬と市場: Tarunの総報酬 ($USD 150.33K ) は、 Indian市場 ($USD 442.54K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Tarunの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Tarun Arora (52 yo)

5.4yrs

在職期間

₹12,542,000

報酬

Mr. Tarun G. Arora has been Chief Executive Officer of Zydus Wellness Limited since January 2019 and is instrumental in accelerating the growth on back of innovations, expanding the geographies for the bus...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Tarun Arora	CEO & Whole Time Director	5.4yrs	₹12.54m	0.0031% ₹ 3.6m
Umesh Parikh	Chief Financial Officer	6.3yrs	₹12.02m	データなし
Nandish Joshi	Company Secretary	1.9yrs	データなし	データなし

5.4yrs

平均在職期間

経験豊富な経営陣: 531335の経営陣は経験豊富で経験豊富です（平均在職期間は5.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Tarun Arora	CEO & Whole Time Director	9.1yrs	₹12.54m	0.0031% ₹ 3.6m
Sharvil Patel	Non-Executive Chairman	15.2yrs	₹800.00k	0.00084% ₹ 954.5k
Ganesh Nayak	Non-Executive Director	17.9yrs	₹1.20m	0.010% ₹ 11.7m
Dharmishtaben Raval	Non-Executive Independent Director	5.3yrs	₹1.40m	データなし
Kulin Lalbhai	Non-Executive & Independent Director	7.6yrs	₹1.70m	データなし
Akhil Monappa	Additional Non Executive & Independent Director	1.1yrs	データなし	データなし
Ashish Bhargava	Nominee Director	5.4yrs	データなし	データなし
Srivishnu Nandyala	Non-Executive Independent Director	5.3yrs	₹1.70m	データなし

6.5yrs

平均在職期間

51yo

平均年齢

経験豊富なボード: 531335の取締役会は経験豊富であると考えられます ( 6.5年の平均在任期間)。

Zydus Wellness マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Zydus Wellness Limited, Annual General Meeting, Aug 02, 2024

Insider recently bought ₹175m worth of stock

Zydus Wellness Limited Announces Resignation of Savyasachi Sengupta as Independent Director

Insider recently bought ₹331m worth of stock

Insider recently bought ₹385m worth of stock

Insider recently bought ₹148m worth of stock

Recent updates

Price target increased by 8.2% to ₹1,883

Dividend of ₹5.00 announced

Zydus Wellness Limited, Annual General Meeting, Aug 02, 2024

Full year 2024 earnings: EPS misses analyst expectations

Zydus Wellness Limited Recommends Final Dividend, Payable on or After August 7, 2024

Zydus Wellness Limited to Report Q4, 2024 Results on May 14, 2024

Insider recently bought ₹175m worth of stock

Consensus EPS estimates fall by 15%

Third quarter 2024 earnings released: EPS: ₹0.05 (vs ₹3.07 in 3Q 2023)

Zydus Wellness Limited to Report Q3, 2024 Results on Feb 08, 2024

Second quarter 2024 earnings released: EPS: ₹0.93 (vs ₹1.33 in 2Q 2023)

Zydus Wellness Limited Announces Resignation of Savyasachi Sengupta as Independent Director

Zydus Wellness Limited to Report Q2, 2024 Results on Nov 06, 2023

Insider recently bought ₹331m worth of stock

Zydus Wellness Limited Approves Final Dividend for the Financial Year Ended March 31, 2023

New minor risk - Dividend sustainability

Zydus Wellness Limited to Report Q1, 2024 Results on Aug 03, 2023

Upcoming dividend of ₹5.00 per share at 0.3% yield

Full year 2023 earnings: EPS misses analyst expectations

Insider recently bought ₹385m worth of stock

Insider recently bought ₹148m worth of stock

Price target decreased by 7.4% to ₹1,813

Zydus Wellness Limited, Annual General Meeting, Aug 03, 2023

Zydus Wellness Limited Appoints Akhil Monappa as Additional Director (Non Executive & Independent Director)

Full year 2023 earnings: EPS misses analyst expectations

Zydus Wellness Limited, Annual General Meeting, Aug 03, 2023

Insider recently bought ₹1.8m worth of stock

Third quarter 2023 earnings released: EPS: ₹3.07 (vs ₹3.66 in 3Q 2022)

CEO & Whole Time Director recently bought ₹301k worth of stock

Second quarter 2023 earnings released: EPS: ₹1.33 (vs ₹3.37 in 2Q 2022)

Insider recently bought ₹16m worth of stock

Insider recently bought ₹9.2m worth of stock

Zydus Wellness Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Zydus Wellness Limited Appoints Nandish P. Joshi as the Company Secretary

Upcoming dividend of ₹5.00 per share

Zydus Wellness Limited to Report First Half, 2023 Results on Nov 14, 2022

Insider recently bought ₹55m worth of stock

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Zydus Wellness Limited Recommends Final Dividend for the Year Ended on March 31, 2022, Payable on or After August 4, 2022

Consensus forecasts updated

Zydus Wellness Limited, Annual General Meeting, Jul 29, 2022

Price target decreased to ₹2,125

Insufficient new directors

Price target decreased to ₹2,125

Insufficient new directors

Insider recently bought ₹757k worth of stock

Zydus Wellness Limited Announces Resignation of Dhanraj P. Dagar as Company Secretary & Compliance Officer, Effective May 10, 2022

Consensus EPS estimates fall by 10%

Price target decreased to ₹2,339

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

CEO & Whole Time Director recently bought ₹812k worth of stock

Second quarter 2022 earnings released: EPS ₹3.37 (vs ₹18.14 loss in 2Q 2021)

Insider recently sold ₹2.3m worth of stock

Price target increased to ₹2,517

Upcoming dividend of ₹5.00 per share

Full year 2021 earnings released: EPS ₹19.55 (vs ₹24.58 in FY 2020)

Full year 2021 earnings released: EPS ₹19.55 (vs ₹24.58 in FY 2020)

Zydus Wellness Limited Recommends Final Dividend

Price target raised to ₹2,266

Third quarter 2021 earnings released: EPS ₹0.27 (vs ₹0.73 in 3Q 2020)

Revenue beats expectations, earnings disappoint

Zydus Announces United States Food and Drug Administration (USFDA) Has Granted `Orphan Drug Designation' (ODD) to Saroglitazar Mg for the Treatment of Patients with Primary Biliary Cholangitis

Zydus Wellness Limited to Report Q3, 2021 Results on Feb 01, 2021

New 90-day high: ₹1,940

New 90-day high: ₹1,919

Price target raised to ₹2,039

Second quarter 2021 earnings released: ₹18.14 loss per share

Revenue and earnings miss expectations

Price target raised to ₹1,877

マネジメント基準チェック /44